日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Elevated intestinal fatty acid-binding protein levels as a marker of portal hypertension and gastroesophageal varices in cirrhosis.

肠道脂肪酸结合蛋白水平升高可作为肝硬化患者门静脉高压和胃食管静脉曲张的标志物

Miuma Satoshi, Miyaaki Hisamitsu, Taura Naota, Kanda Yasuko, Matsuo Satoshi, Tajima Kazuaki, Takahashi Kosuke, Nakao Yasuhiko, Fukushima Masanori, Haraguchi Masafumi, Sasaki Ryu, Ozawa Eisuke, Ichikawa Tatsuki, Nakao Kazuhiko

Hypoglycemia measured by flash glucose monitoring system predicts liver-related events in chronic liver disease patients

通过瞬时血糖监测系统测得的低血糖可预测慢性肝病患者的肝脏相关事件。

Sasaki, Ryu; Taura, Naota; Nakao, Yasuhiko; Fukushima, Masanori; Haraguchi, Masafumi; Miuma, Satoshi; Miyaaki, Hisamitsu; Nakao, Kazuhiko

Change in tartrate-resistant acid phosphatase isoform 5b levels, a marker of bone metabolism, in patients with chronic hepatitis B treated with tenofovir alafenamide

接受替诺福韦艾拉酚胺治疗的慢性乙型肝炎患者中,抗酒石酸酸性磷酸酶同工酶5b水平(一种骨代谢标志物)的变化

Okamura, Takuma; Ichikawa, Tatsuki; Miyaaki, Hisamitsu; Miuma, Satoshi; Motoyoshi, Yasuhide; Yamashima, Mio; Yamamichi, Shinobu; Koike, Makiko; Nakano, Yusuke; Honda, Tetsurou; Yajima, Hiroyuki; Miyazaki, Osamu; Kuribayashi, Yasutaka; Ikeda, Tomonari; Taura, Naota; Nakao, Kazuhiko

Comparison of calculated body muscle mass and SARC-F as methods of screening for sarcopenia in patients with chronic liver disease

比较计算的体肌量和SARC-F作为慢性肝病患者肌少症筛查方法

Ichikawa, Tatsuki; Miyaaki, Hisamitsu; Miuma, Satoshi; Motoyoshi, Yasuhide; Yamashima, Mio; Yamamichi, Shinobu; Koike, Makiko; Nakano, Yusuke; Honda, Tetsurou; Yajima, Hiroyuki; Uehara, Ryouhei; Miyazaki, Osamu; Kuribayashi, Yasutaka; Kira, Keiji; Taura, Naota; Nakao, Kazuhiko

Indices calculated by serum creatinine and cystatin C as predictors of liver damage, muscle strength and sarcopenia in liver disease

血清肌酐和胱抑素C计算的指标可作为肝病中肝损伤、肌肉力量和肌少症的预测因子

Ichikawa, Tatsuki; Miyaaki, Hisamitsu; Miuma, Satoshi; Motoyoshi, Yasuhide; Yamashima, Mio; Yamamichi, Shinobu; Koike, Makiko; Takahashi, Youichi; Honda, Tetsurou; Yajima, Hiroyuki; Uehara, Ryouhei; Hino, Naoyuki; Hirata, Ryousuke; Taura, Naota; Nakao, Kazuhiko

Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir

接受达克拉他韦/阿舒那韦治疗的慢性丙型肝炎病毒感染患者血清LDL、PCSK9和microRNA-122的变化

Ichikawa, Tatsuki; Miyaaki, Hisamitsu; Miuma, Satoshi; Taura, Naota; Motoyoshi, Yasuhide; Akahoshi, Hiroshi; Nakamura, Junpei; Takahashi, Youichi; Honda, Tetsurou; Yajima, Hiroyuki; Uehara, Ryouhei; Hino, Naoyuki; Narita, Syouhei; Tanaka, Hisaya; Sasaki, Seina; Nakao, Kazuhiko

Geranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in cultured human hepatic stellate cells and reduces liver fibrosis in carbon tetrachloride-treated mice

香叶基香叶基丙酮可减弱培养的人肝星状细胞的纤维化活性并诱导其凋亡,还能减轻四氯化碳处理的小鼠的肝纤维化。

Senoo, Takemasa; Sasaki, Ryu; Akazawa, Yuko; Ichikawa, Tatsuki; Miuma, Satoshi; Miyaaki, Hisamitsu; Taura, Naota; Nakao, Kazuhiko

Current characteristics of hemophilia patients co-infected with HIV/HCV in Japan

日本血友病合并HIV/HCV感染患者的现状

Miuma, Satoshi; Hidaka, Masaaki; Takatsuki, Mitsuhisa; Natsuda, Koji; Soyama, Akihiko; Miyaaki, Hisamitsu; Kanda, Yasuko; Tamada, Yoko; Shibata, Hidetaka; Ozawa, Eisuke; Taura, Naota; Eguchi, Susumu; Nakao, Kazuhiko

Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients

血清外泌体microRNA-122和microRNA-21作为经动脉化疗栓塞治疗的肝细胞癌患者的预测性生物标志物

Suehiro, Tomoyuki; Miyaaki, Hisamitsu; Kanda, Yasuko; Shibata, Hidetaka; Honda, Takuya; Ozawa, Eisuke; Miuma, Satoshi; Taura, Naota; Nakao, Kazuhiko

Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice

托伊卡霉素可减轻游离脂肪酸诱导的培养肝细胞脂肪变性和细胞凋亡,并改善小鼠非酒精性脂肪肝疾病。

Takahara, Ikuko; Akazawa, Yuko; Tabuchi, Maiko; Matsuda, Katsuya; Miyaaki, Hisamitsu; Kido, Youko; Kanda, Yasuko; Taura, Naota; Ohnita, Ken; Takeshima, Fuminao; Sakai, Yusuke; Eguchi, Susumu; Nakashima, Masahiro; Nakao, Kazuhiko